Yes, there’s a tradeoff between accuracy and cost/speed. ABT’s PCR-based test, which runs on its m2000 systems owned by hospitals and major laboratories (#msg-154427024), is too slow and too expensive for the kind of mass testing envisioned for ABT’s BinaxNOW (lateral-flow) test announced yesterday.
Market Data 
Markets 
AI
